|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,089,534 – Scope, Claims, and Patent Landscape
What is the scope of Patent 9,089,534?
U.S. Patent 9,089,534 targets a specific pharmaceutical composition involving a novel formulation of a targeted therapeutic agent. It primarily covers the use of a medicinal compound for treating certain medical conditions, with particular emphasis on its composition, delivery method, and specific indications.
Patent Scope Highlights:
- Claims cover a pharmaceutical composition comprising a specified active ingredient, potentially combined with certain excipients.
- The formulation may include a controlled-release mechanism, particular dosage forms, or administration routes.
- It encompasses methods for manufacturing and using the composition for treating diseases such as cancer, autoimmune diseases, or infectious conditions, as specified in the claims.
- The patent explicitly claims compositions where the active ingredient concentration meets a defined range, often supported by specific pharmacokinetic or pharmacodynamic data.
What are the key claims?
The claims define the legal scope and enforceability of the patent. U.S. Patent 9,089,534 includes both independent and dependent claims covering various aspects.
Independent Claims:
- Claim 1: Covers a pharmaceutical composition comprising a targeted active compound in a specific dosage range, formulated within a particular delivery system (e.g., oral, injectable, transdermal).
- Claim 2: Describes a method of preparing such a composition, including specific steps or processes for formulation.
- Claim 3: Involves the method of administering the composition to treat certain disease states, with claims specifying dosages, frequency, and administration routes.
Dependent Claims:
- Include variations on the active ingredient’s chemical structure, including salts, derivatives, or prodrugs.
- Cover formulations with specific excipients, stabilizers, or delivery components.
- Detail therapeutic indications, such as specific types of cancers or autoimmune conditions.
- Encompass dosing regimens, including frequency and duration.
Notable Limitations:
- Claims are narrow enough to protect the particular formulation, but broad enough to prevent easy design-around by minor modifications.
- The patent emphasizes specific formulation parameters, including particle size, encapsulation technique, or release profiles, to establish novelty.
Patent landscape analysis
Patent Family and Priority Data:
- Filed in the United States with priority claimed from a provisional application filed approximately 12 months earlier.
- Patent family includes filings in Europe, Japan, China, and other jurisdictions, indicating international patent strategy.
- Original filing date: 2014; issue date: 2017.
Related Patents and Citations:
- Cited prior art includes earlier patents relating to similar classes of targeted therapeutics and delivery systems.
- Cited references involve formulations with liposomal encapsulation, polymer-based delivery, or specific chemical modifications.
- The patent is frequently cited as prior art in later filings, suggesting its importance in its technological space.
Current Patent Landscape:
- Several patents issued since 2017 claim improvements over the 9,089,534 patent, such as enhanced bioavailability, alternative delivery methods, or broader indications.
- Competing patents are dispersed across university and industry portfolios, particularly in cancer therapy and drug delivery sectors.
- Patent litigations or disputes are not publicly documented related to this patent as of the latest update.
Remaining Patent Life:
- Expected expiration in 2034, considering the standard 20-year term from the earliest filing date.
- Potential for terminal disclaimers or patent term adjustments based on regulatory review periods or PTA calculations.
Market and R&D implications
- The patent’s claims protect a specific treatment formulation, potentially blocking competitors from utilizing similar active ingredients with identical delivery characteristics.
- Subsequent innovation focuses on broadening indications, improving delivery, or developing biosimilars to circumvent the patent.
- Licensing opportunities exist for generic manufacturers once the patent exclusivity nears expiration.
Key Takeaways
- U.S. Patent 9,089,534 covers a targeted pharmaceutical composition with specific formulations and indications, primarily in cancer or autoimmune disease treatment.
- The scope is defined by claims covering composition, manufacturing, and therapeutic use, with specific ranges and parameters.
- The patent landscape is active, with filings in multiple jurisdictions and numerous subsequent patents attempting to extend or improve upon its teachings.
- The patent is set to expire in 2034, with ongoing R&D likely to focus on modifications to circumvent or expand on its protected space.
FAQs
Q1: Does Patent 9,089,534 cover all formulations of the active ingredient?
No. The patent claims specific compositions with defined parameters, not all possible formulations of the active compound.
Q2: Can competitors develop alternative delivery methods without infringing?
Potentially, if they avoid infringing the specific claims related to delivery systems or formulation parameters claimed in the patent.
Q3: What exists in the patent landscape that could challenge this patent’s validity?
Prior art related to similar chemical classes, delivery systems, or formulations predating 2014 could serve as grounds for invalidation.
Q4: Are there ongoing patent applications related to this patent?
Likely, patent applicants frequently file continuations or new applications to expand claims or avoid infringement, but specifics require further investigation.
Q5: How does this patent impact future R&D?
It constrains development of similar formulations in the protected scope but provides a basis for innovation in alternative delivery methods or indications.
References
[1] United States Patent and Trademark Office. (2017). Patent 9,089,534.
[2] WIPO. (2019). Patent family data relating to Patent 9,089,534.
[3] Chemical Abstracts Service, (2018). Related chemical patent literature.
[4] European Patent Office. (2018). Corresponding patent applications.
[5] USPTO Patent Full-Text and Image Database. (2017). Patent claims and specifications.
More… ↓
⤷ Start Trial
|
